Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline
remove_circle_outline

Journals

Article Types

Countries / Regions

Search Results (4)

Search Parameters:
Authors = Yogambigai Rajamoorthy

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
16 pages, 941 KB  
Article
Willingness to Pay (WTP) for COVID-19 Vaccine Booster Dose and Its Determinants in Indonesia
by Harapan Harapan, Malik Sallam, Raisha Fathima, Hendrix Indra Kusuma, Samsul Anwar, Widhy Yudistira Nalapraya, Adityo Wibowo, Ketut Dewi Kumara Wati, Ayunda Medina, Anna Hanifa Defrita, Yesi Astri, Arie Prasetyowati, Nurfarahin Nurfarahin, Afriyani Khusna, Setya Oktariana, Sarifuddin Anwar, Milza Oka Yussar, Siti Khotimah, Bahagia Willibrordus Maria Nainggolan, Putri Rizki Amalia Badri, Raden Argarini, Wira Winardi, Khan Sharun, Rosaria Indah, Yogambigai Rajamoorthy, Abram L. Wagner and Mudatsir Mudatsiradd Show full author list remove Hide full author list
Infect. Dis. Rep. 2022, 14(6), 1017-1032; https://doi.org/10.3390/idr14060101 - 11 Dec 2022
Cited by 9 | Viewed by 6075
Abstract
Willingness to pay (WTP) for booster doses of coronavirus disease 2019 (COVID-19) vaccines is an under studied research topic. Therefore, the current study aimed to investigate the WTP for the booster doses of COVID-19 vaccines and its predictors in Indonesia using an online [...] Read more.
Willingness to pay (WTP) for booster doses of coronavirus disease 2019 (COVID-19) vaccines is an under studied research topic. Therefore, the current study aimed to investigate the WTP for the booster doses of COVID-19 vaccines and its predictors in Indonesia using an online survey distributed all over the provinces of this low-middle-income country. The WTP was evaluated using a basic dichotomous contingent valuation approach, and its associated determinants were evaluated using a linear regression model. Out of 2935 responders, 66.2% (1942/2935) were willing to pay for a booster dose of the COVID-19 vaccine. The majority of respondents (63.5%) were willing to pay within a price range of 100,000–500,000 Indonesian rupiah (IDR), i.e., USD 6.71–33.57. Being older than 40 years, having a higher educational level, having a higher income, knowing and understanding that booster doses were important, and having a vaccine status that is certified halal (permissible in Islamic law), were all associated with a higher WTP for the booster dose of COVID-19 vaccines. The study findings imply that the WTP for a booster dose of COVID-19 vaccination in Indonesia is lower compared to acceptance of vaccines provided free of charge. This WTP data can be utilized to develop a pricing scheme for the booster doses of COVID-19 vaccination in the country with potential benefits in other low-income countries. The government may be required to provide subsidies for the herd immunity vaccination process to proceed as anticipated. Furthermore, the public community must be educated on the importance of vaccination as well as the fact that the COVID-19 epidemic is far from being over. Full article
(This article belongs to the Special Issue Epidemiology and Prevention of Vaccine Preventable Diseases)
20 pages, 1162 KB  
Article
Drivers of and Barriers to COVID-19 Vaccine Booster Dose Acceptance in Indonesia
by Harapan Harapan, Raisha Fathima, Hendrix Indra Kusuma, Samsul Anwar, Widhy Yudistira Nalapraya, Adityo Wibowo, Ketut Dewi Kumara Wati, Ayunda Medina, Anna Hanifa Defrita, Yesi Astri, Arie Prasetyowati, Nurfarahin Nurfarahin, Afriyani Khusna, Setya Oktariana, Sarifuddin Anwar, Milza Oka Yussar, Siti Khotimah, Bahagia Willibrordus Maria Nainggolan, Putri Rizki Amalia Badri, Raden Argarini, Wira Winardi, Rosaria Indah, Malik Sallam, Yogambigai Rajamoorthy, Abram L. Wagner and Mudatsir Mudatsiradd Show full author list remove Hide full author list
Vaccines 2022, 10(12), 1981; https://doi.org/10.3390/vaccines10121981 - 22 Nov 2022
Cited by 13 | Viewed by 4846
Abstract
Obtaining a booster dose of coronavirus disease 2019 (COVID-19) vaccine is required to maintain the protective level of neutralizing antibodies and therefore herd immunity in the community, and the success of booster dose programs depends on public acceptance. The aim of this study [...] Read more.
Obtaining a booster dose of coronavirus disease 2019 (COVID-19) vaccine is required to maintain the protective level of neutralizing antibodies and therefore herd immunity in the community, and the success of booster dose programs depends on public acceptance. The aim of this study was to determine the acceptance of a booster dose of COVID-19 vaccine and its drivers and barriers in Indonesia. A cross-sectional survey was conducted in the provinces of Indonesia between 1 and 15 August 2022. Individuals who completed the primary series of the COVID-19 vaccine were asked about their acceptance of a booster dose. Those who refused the booster dose were questioned about their reasons. A logistic regression was used to determine the determinants associated with rejection of a booster dose of COVID-19 vaccine. A total of 2935 respondents were included in the final analysis. With no information on the efficacy and safety of the COVID-19 vaccine, 95% of respondents agreed to receive a booster dose if it were provided for free by the government. This acceptance was reduced to only 50.3% if the vaccine had a 75% efficacy with a 20% chance of side effects. The adjusted logistic regression analysis indicated that there were eight factors associated with the rejection of the booster dose: age, marital status, religion, occupation, type of the first two vaccines received, knowledge regarding the importance of the booster dose, belief that natural immunity is sufficient to prevent COVID-19 and disbelief in the effectiveness of the booster dose. In conclusion, the hesitancy toward booster doses in Indonesia is influenced by some intrinsic factors such as lack of knowledge on the benefits of the booster dose, worries regarding the unexpected side effects and concerns about the halal status of the provided vaccines and extrinsic determinants such as the effectiveness and safety of the vaccine. These findings suggest the need for more campaigns and promotions regarding the booster dose benefits to increase its acceptance. Full article
(This article belongs to the Special Issue Public Psychobehavioral Responses towards Vaccination)
Show Figures

Figure 1

10 pages, 258 KB  
Article
Differential Effect of Vaccine Effectiveness and Safety on COVID-19 Vaccine Acceptance across Socioeconomic Groups in an International Sample
by Stefania Kerekes, Mengdi Ji, Shu-Fang Shih, Hao-Yuan Chang, Harapan Harapan, Yogambigai Rajamoorthy, Awnish Singh, Shailja Kanwar and Abram L. Wagner
Vaccines 2021, 9(9), 1010; https://doi.org/10.3390/vaccines9091010 - 11 Sep 2021
Cited by 25 | Viewed by 5931
Abstract
Controlling the spread of SARS-CoV-2 will require high vaccination coverage, but acceptance of the vaccine could be impacted by perceptions of vaccine safety and effectiveness. The aim of this study was to characterize how vaccine safety and effectiveness impact acceptance of a vaccine, [...] Read more.
Controlling the spread of SARS-CoV-2 will require high vaccination coverage, but acceptance of the vaccine could be impacted by perceptions of vaccine safety and effectiveness. The aim of this study was to characterize how vaccine safety and effectiveness impact acceptance of a vaccine, and whether this impact varied over time or across socioeconomic and demographic groups. Repeated cross-sectional surveys of an opt-in internet sample were conducted in 2020 in the US, mainland China, Taiwan, Malaysia, Indonesia, and India. Individuals were randomized into receiving information about a hypothetical COVID-19 vaccine with different safety and effectiveness profiles (risk of fever 5% vs. 20% and vaccine effectiveness 50% vs. 95%). We examined the effect of the vaccine profile on vaccine acceptance in a logistic regression model, and included interaction terms between vaccine profile and socioeconomic/demographic variables to examine the differences in sensitivity to the vaccine profile. In total, 12,915 participants were enrolled in the six-country study, including the US (4054), China (2797), Taiwan (1278), Malaysia (1497), Indonesia (1527), and India (1762). Across time and countries, respondents had stronger preferences for a safer and more effective vaccine. For example, in the US in November 2020, acceptance was 3.10 times higher for a 95% effective vaccine with a 5% risk of fever, vs a vaccine 50% effective, with a 20% risk of fever (95% CI: 2.07, 4.63). Across all countries, there was an increase in the effect of the vaccine profile over time (p < 0.0001), with stronger preferences for a more effective and safer vaccine in November 2020 compared to August 2020. Sensitivity to the vaccine profile was also stronger in August compared to November 2020, in younger age groups, among those with lower income; and in those that are vaccine hesitant. Uptake of COVID-19 vaccines could vary in a country based upon effectiveness and availability. Effective communication tools will need to be developed for certain sensitive groups, including young adults, those with lower income, and those more vaccine hesitant. Full article
(This article belongs to the Special Issue SARS-CoV-2 (COVID-19) Vaccination and Compliance/Hesitancy)
14 pages, 464 KB  
Article
Willingness to Participate and Associated Factors in a Zika Vaccine Trial in Indonesia: A Cross-Sectional Study
by Harapan Harapan, Mudatsir Mudatsir, Amanda Yufika, Yusuf Nawawi, Nur Wahyuniati, Samsul Anwar, Fitria Yusri, Novi Haryanti, Nanda Putri Wijayanti, Rizal Rizal, Devi Fitriani, Nurul Fadhliati Maulida, Muhammad Syahriza, Ikram Ikram, Try Purwo Fandoko, Muniati Syahadah, Febrivan Wahyu Asrizal, Kurnia F. Jamil, Yogambigai Rajamoorthy, Abram Luther Wagner, David Alexander Groneberg, Ulrich Kuch, Ruth Müller, R. Tedjo Sasmono and Allison Imrieadd Show full author list remove Hide full author list
Viruses 2018, 10(11), 648; https://doi.org/10.3390/v10110648 - 18 Nov 2018
Cited by 13 | Viewed by 5963
Abstract
One of the crucial steps during trials for Zika and other vaccines is to recruit participants and to understand how participants’ attitudes and sociodemographic characteristics affect willingness to participate (WTP). This study was conducted to assess WTP, its explanatory variables, and the impact [...] Read more.
One of the crucial steps during trials for Zika and other vaccines is to recruit participants and to understand how participants’ attitudes and sociodemographic characteristics affect willingness to participate (WTP). This study was conducted to assess WTP, its explanatory variables, and the impact of financial compensation on WTP in Indonesia. A health facility-based cross-sectional study was conducted in eleven regencies in the Aceh and West Sumatra provinces of Indonesia. Participants were recruited via a convenience sampling method and were interviewed. The associations between explanatory variables and WTP were assessed using a two-step logistic regression analysis. A total of 1,102 parents were approached, and of these 956 (86.8%) completed the interview and were included in analysis. Of those, 144 (15.1%) were willing to participate in a Zika vaccine trial without a financial compensation. In the multivariate analysis, WTP was tied to an age of more than 50 years old, compared to 20–29 years (odds ratio (OR): 5.0; 95% confidence interval (CI): 2.37–10.53), to being female (OR: 2.20; 95% CI: 1.11–4.37), and to having heard about Zika (OR: 2.41; 95% CI: 1.59–3.65). Participants’ WTP increased gradually with higher financial compensation. The rate of WTP increased to 62.3% at the highest offer (US$ 350.4), and those who were still unwilling to participate (37.7%) had a poorer attitude towards childhood vaccination. This study highlights that pre-existing knowledge about Zika and attitudes towards childhood vaccination are important in determining community members being willing to participate in a vaccine trial. Financial incentives are still an important factor to enhance participant recruitment during a vaccine trial. Full article
(This article belongs to the Special Issue 6th Pan-American Dengue Research Network Meeting)
Show Figures

Figure 1

Back to TopTop